MARIMED INC. (MRMD): Results of Operations and Financial Condition
MARIMED INC. (MRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9918-kearningsq22026.htm EX-99.1 Document Exhibit 99.1 MariMed Reports Second Quarter 2026 Earnings NORWOOD, MA, August 12, 2026 - MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives e
How this was made
The 30-second read
Why it matters
The 8-K reports Q2 2026 financial and operating highlights, including sequential revenue growth, adjusted EBITDA improvement, and a stated positive cash flow from operations, plus a strategy update toward brand expansion and capital-light market entry.
Market read
Traders can reassess near-term momentum in MRMD based on the earnings datapoints and the upcoming Aug 13 conference call.
What to watch
The text emphasizes federal reform catalysts (rescheduling, 280E relief, banking reform) but provides no measurable policy timeline or quantified benefit, so the market may discount it until legislation or regulatory action is concrete.
Background
MariMed is a multi-state cannabis operator focused on wholesale and retail under brands such as Betty’s Eddies and Vibations.
Ticker impact
MariMed reported Q2 2026 results with revenue $41.9M, GAAP net loss $(3.6)M, and non-GAAP adjusted EBITDA $3.9M.
Likely modest positive reaction versus prior quarter, with follow-through dependent on guidance and federal reform expectations.
The filing is a primary earnings disclosure (8-K with Exhibit 99.1) and includes multiple directional operating metrics (sequential wholesale and retail growth, adjusted EBITDA up, positive operating cash flow), but it does not provide explicit forward guidance or consensus comparisons in the provided text.
Market effects
Reinforces the multi-state operator narrative that margins can stabilize (non-GAAP gross margin flat at 40%) while brands drive retail and wholesale mix.
No specific regional macro impact beyond performance in MariMed’s core states (MA, MD, IL, DE).
Limited, as the disclosure is company-specific within the US cannabis operator space.
Counterpoint
GAAP net loss widened year over year and non-GAAP results may mask underlying cost pressures; investors may fade the story if cash flow is not sustained.
Key entities
- companyMariMed Inc.
Subject of the SEC 8-K, reporting Q2 2026 results and operational metrics.
- personJon Levine
CEO quoted on performance drivers and forward strategy.
